KOSDAQElectronic Components024850

HLB innoVation

₩14,840▲ 10.99%2026-11-18 close
Market Cap
₩514.1B
Turnover
₩2.7B
Volume
180K
Shares out.
34.7M
PER
—
PBR
1.7×
EPS
-₩911
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Four Quarters of Revenue Growth, Losses Still Persist

Revenue has risen for four straight quarters through Q3 2026, while operating losses and controlling-shareholder net losses have continued over the same span.

  1. 1

    Revenue flow: Q3 2026 revenue was KRW 11.9 billion, up 57.7% year on year, and consolidated revenue for January to September 2026 rose 32.6% per the quarterly report.

  2. 2

    Profit structure: the 2025 operating loss was KRW 37.6 billion (operating margin -116.4%), and the controlling-shareholder net loss widened to KRW 33.4 billion from 2024.

  3. 3

    Business mix: lead frames accounted for about 62% and contact pins for about 20% of consolidated revenue in January to September 2026.

  4. 4

    Cash flow: operating cash flow was KRW -30.1 billion in 2025, and the cumulative January to September 2026 operating cash flow was a net outflow of KRW 22.32 billion per the quarterly report.

  5. 5

    Bio option: the CAR-T candidates SynKIR-110 and SynKIR-310 at U.S. subsidiary Verismo Therapeutics are both in Phase 1 clinical trials.

02

Business structure

HLB innoVation runs a semiconductor component business used in chip inspection processes alongside a bio business. In components, it produces lead frames and contact pins for test sockets, which made up about 62.33% (KRW 19.92 billion) and 19.90% (KRW 6.36 billion) of consolidated revenue in January to September 2026.

Lead frames are metal frames that support a chip and connect it to external circuits, while contact pins make contact between the chip and inspection equipment.

The company attributes higher customer demand, centered on contact pins for test sockets, to the expansion of the AI semiconductor market and a recovery in the chip cycle. It says it has invested about KRW 2 billion a year in production facilities since joining the HLB Group in 2023 to improve quality and yield.

On purchasing, it introduced a strategic procurement system and diversified suppliers to cut raw material and manufacturing costs. Production moved from a 24-hour rotating shift to a 16-hour two-shift system, cutting operating hours by about 33% while keeping output similar to before.

The bio business sits with the U.S. subsidiary Verismo Therapeutics, where the solid tumor candidate SynKIR-110 is in a Phase 1 trial in the United States.

The blood cancer candidate SynKIR-310 is also in Phase 1, and the company said no major safety issues appeared at the existing dose cohorts, so higher-dose evaluation has begun. The company plans to expand its component production base through quality and delivery management.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩7.6B-₩9.5B−126.2%
2025Q4₩8.2B-₩8.7B−106.1%
2026Q1₩9.4B-₩10.4B−109.9%
2026Q2₩10.6B-₩9.2B−87.2%
2026Q3₩11.9B-₩7.2B−60.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩50.7B₩800M-₩800M1.7%−5.6%153.5%
2023₩20.6B-₩900M-₩800M−4.6%−1.3%61.6%
2024₩25.4B-₩11.9B-₩12.4B−46.9%−5.0%6.4%
2025₩32.3B-₩37.6B-₩33.4B−116.4%−15.9%21.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-12

04

Earnings analysis

On a disclosed annual basis, revenue fell from KRW 50.7 billion in 2022 to KRW 20.6 billion in 2023, a 59.4% decline, then rose 23.2% to KRW 25.4 billion in 2024 and 27.2% to KRW 32.3 billion in 2025, growing for two straight years. 2022 was the largest year of the four and 2023 the smallest.

Operating profit of KRW 848 million in 2022 turned into an operating loss of KRW 938 million in 2023, then widened to KRW 11.9 billion in 2024 and KRW 37.6 billion in 2025.

The operating margin moved from 1.7% in 2022 to -4.6% in 2023, -46.9% in 2024 and -116.4% in 2025, and the loss widened in 2025 even though revenue grew. For January to September 2026 on a consolidated basis, selling and administrative expenses were KRW 32.19 billion, well above gross profit of KRW 5.35 billion.

The controlling-shareholder net loss was KRW 844 million in 2022, KRW 755 million in 2023 (a smaller loss), KRW 12.4 billion in 2024 and KRW 33.4 billion in 2025, while the net loss including non-controlling interests was KRW 33.7 billion in 2025.

The debt-to-equity ratio fell from 153.5% in 2022 to 21.4% in 2025, and total liabilities at the end of 2025 were KRW 47.4 billion. Operating cash flow went from KRW 1 billion in 2022 and KRW 257 million in 2023 to KRW -7.9 billion in 2024 and KRW -30.1 billion in 2025.

Quarterly revenue rose from KRW 7.56 billion in Q3 2025 to KRW 11.9 billion in Q3 2026, four consecutive quarterly increases, and the operating loss narrowed to KRW 7.23 billion in Q3 2026 from KRW 9.54 billion a year earlier.

However, the operating loss widened to KRW 10.4 billion in Q1 2026 from the prior quarter, and the controlling-shareholder net loss over the latest four quarters totaled KRW 31.5 billion.

The company said its standalone operating profit has been positive for six straight quarters since Q2 2025, but that figure uses a different basis from the consolidated results, so it should be read alongside the disclosed operating losses.

Per the quarterly report, the consolidated operating loss for January to September 2026 was reported at KRW 26.84 billion.

05

Industry analysis

The clearest demand driver on the customer side is AI semiconductors. The company says the expansion of the AI chip market and a recovery in the semiconductor cycle lifted demand for contact pins used in test sockets.

Because this is the company's own explanation, it is difficult to use as an independent gauge of overall industry supply or cycle position. The company cites four consecutive quarters of revenue growth through Q3 2026 as evidence of rising demand.

According to November 2026 reports, it was selected for three government and local support projects with total project costs of about KRW 3.6 billion, of which about KRW 2.1 billion (58%) is covered by external support.

The projects include AI-based quality prediction, automated inspection and robot introduction in the ultrasonic cleaning process. The company said it will respond steadily to growing customer demand in AI and automotive electronics.

It emphasizes cost competitiveness as its core advantage, citing better defect rates and maintained output after the shift to two-shift operations. Verified data on market share or price comparisons against peers is limited, so this segment relies heavily on the company's own explanations.

06

Outlook

The company's stated direction is to raise productivity and quality competitiveness and to keep management focused on profitability. It said it will continue investing in production and inspection infrastructure in line with changes in demand from AI semiconductors and other end markets.

The three AI support projects are scheduled to wrap up in phases by August 2027. On the bio side, a mid-stage Phase 1 readout for SynKIR-310 was reported in August 2026 as planned for a global conference in the second half of 2026.

The company said SynKIR-110 showed good safety in its first three dose cohorts without severe cytokine release syndrome or neurotoxicity, and the study was selected for a plenary session at AACR 2026. The next periodic report is the 2026 annual report, which will disclose Q4 2026 results.

Key points to watch are whether revenue growth continues and whether the narrowing of operating losses holds. Operating cash flow was a net outflow in January to September 2026 as well, so whether cash generation turns positive is the important checkpoint for the next periodic report.

07

Valuation

PER
—
PBR
1.7×
ROE
-13.7%
EPS
-₩911
BPS
₩7,955
Dividend per share
₩0

Because the controlling-shareholder net loss over the latest four quarters totaled KRW 31.5 billion, the price-to-earnings ratio cannot be calculated. The price-to-book ratio is above 1x, which means the stock trades at a premium to book value.

Total equity at the end of 2025 was KRW 221.3 billion, of which KRW 210.5 billion belonged to controlling shareholders, so the price is being read against a sizable equity base. The company pays no dividend, so dividend-based valuation comparisons are not currently possible.

Controlling-shareholder losses ran from 2022 through 2025, which makes historical earnings-based multiple bands hard to use as a reference. Operating cash flow was a net outflow in both 2025 and January to September 2026, so cash-flow-based metrics have not yet turned positive.

How to read the premium to book value depends on whether more weight goes to the speed of profit recovery in semiconductor components or to the value of the bio pipeline. The starting point for interpreting valuation is the gap between the standalone profit claim and the consolidated loss.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-12

08

Bull factors

Revenue growth continues

Q3 2026 revenue was KRW 11.9 billion, up 57.7% year on year, and it has risen for four straight quarters since Q4 2025. Consolidated revenue for January to September 2026 rose 32.6% per the quarterly report. Annual revenue also grew in 2024 and 2025, extending the expansion trend.

Cost and production efficiency gains

The Q3 2026 operating loss narrowed to KRW 7.23 billion from KRW 9.54 billion a year earlier. The company said its two-shift change cut operating hours by about 33% while keeping output, and that better defect rates and supplier diversification lowered manufacturing costs. Annual facility investment of about KRW 2 billion since 2023 underpins the yield gains.

Early bio pipeline data

The company said SynKIR-110 showed good safety in the first three dose cohorts of its U.S. Phase 1 trial, with no severe cytokine release syndrome or neurotoxicity. The study was selected for an oral presentation in a plenary session at AACR 2026. SynKIR-310 moved into higher-dose evaluation after no major safety issues appeared in the existing cohorts.

09

Bear factors

Accumulated losses

The 2025 operating loss widened to KRW 37.6 billion from KRW 11.9 billion in 2024, and the controlling-shareholder net loss was KRW 33.4 billion. The latest four quarters of controlling-shareholder net losses totaled KRW 31.5 billion, and the Q1 2026 operating loss of KRW 10.4 billion was larger than the prior quarter. The operating margin fell from 1.7% in 2022 to -116.4% in 2025.

Weaker cash generation

Since 2024, cash has flowed out of operations rather than in. January to September 2026 still showed a net outflow of KRW 22.32 billion per the quarterly report. The outflow was smaller than the KRW 25.84 billion a year earlier, but cash generation has not turned positive.

SG&A burden and basis differences

Consolidated selling and administrative expenses for January to September 2026 were KRW 32.19 billion, well above gross profit of KRW 5.35 billion. The standalone operating profit the company announced uses a different scope from the consolidated operating loss, so the two are not directly comparable. That gap makes the earnings hard to read through a single figure.

10

Risk factors

Financing and liquidity

Operating cash flow has been a net outflow since 2024. Press coverage highlighted convertible bonds and cash flow as points to watch, and financing choices could dilute shareholder value.

Total liabilities at the end of 2025 were KRW 47.4 billion with a debt-to-equity ratio of 21.4%, and continued losses could erode equity and cash capacity.

Product concentration

Lead frames and contact pins together made up about 82% of consolidated revenue in January to September 2026, so product concentration is high. The company cites rising end-market demand, but a downturn in the chip market or lower customer orders could weaken the revenue trend. Whether the four-quarter growth streak continues is the way to test this risk.

Clinical uncertainty

SynKIR-110 and SynKIR-310 are both in Phase 1, so whether early safety holds as doses and patient numbers increase is uncertain. Even positive clinical results take time to reach revenue or earnings. Bio progress is some distance from changing the current consolidated loss structure.

11

What to watch next

  1. Second half of 2026 (conference date unconfirmed)

    Interim Phase 1 results for SynKIR-310 at Verismo Therapeutics. A global conference presentation in the second half of 2026 was planned as of an August 2026 report. Whether safety and anti-tumor activity hold at higher doses is the key checkpoint for the bio option.

  2. End of March 2027

    Filing of the 2026 annual report, which will disclose Q4 and full-year 2026 revenue, operating loss and operating cash flow. The key questions are whether the operating loss narrows from KRW 37.6 billion in 2025 and whether operating cash flow turns positive for the year.

  3. Mid-May 2027

    Q1 2027 quarterly report. It shows whether the revenue increases since Q4 2026 continue, whether the operating loss widens again as it did in Q1 2026, and any financing changes such as convertible bonds.

  4. By August 2027

    Phased completion of three AI and smart factory support projects, with total costs of about KRW 3.6 billion and about KRW 2.1 billion in external support. Whether automated inspection and robot introduction show up in productivity measures is the point to verify.

12

Overall view

HLB innoVation is a company whose main products are semiconductor lead frames and contact pins, and it also runs CAR-T clinical programs through a U.S. subsidiary. Revenue rose for four straight quarters through Q3 2026, and the Q3 operating loss narrowed from a year earlier.

On the other hand, operating and controlling-shareholder net losses widened in 2024 and 2025, and operating cash flow was a net outflow of KRW 30.1 billion in 2025.

The company says its standalone operating profit has been positive for six straight quarters, but the consolidated operating loss for January to September 2026 was reported at KRW 26.84 billion. The gap between these two bases is the starting point for reading the results.

Bullish factors include revenue growth, production efficiency after the two-shift change, and early safety data from the clinical programs, while bearish factors include the accumulated losses, net cash outflows and product concentration.

Valuation is mixed, with no calculable PER and a price-to-book ratio above 1x, so readings depend on whether more weight goes to the narrowing losses or to the bio pipeline. The next checkpoints are the annual loss and operating cash flow in the 2026 annual report, and the interim SynKIR-310 results.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. etoday.co.kr
  2. medipana.com
  3. newspim.com
  4. enewstoday.co.kr
  5. supple.kr
  6. ittimes.com
  7. thebionews.net
  8. fnnews.com
  9. newspim.com
  10. m.news.nate.com
  11. thebionews.net
  12. newstnt.com
  13. lawissue.co.kr
  14. paxetv.com
  15. cbci.co.kr

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis